RNAi News and Research

RSS

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

Scientists create genetic map to identify mechanism behind heart abnormalities

Though heart disease is a major cause of disability and death, very little is understood about its genetic underpinnings. Recently, an international team of investigators at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Sanford-Burnham Medical Research Institute (Sanford-Burnham) and other organizations shed new light on the subject.

2 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

31 Mar 2010

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Japanese Patent Office has granted claims in a second patent application (JP Application Number 2006-317758) for the Tuschl II patent series, entitled "RNA Interference Mediating Small RNA Molecules." In May 2008, the Japanese Patent Office granted a related set of claims in the Tuschl II patent series (JP 4 095 895).

31 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in August 2009, the companies are leveraging Silence's proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate functional delivery of RNA interference (RNAi) therapeutics to specific disease targets in the body.

30 Mar 2010

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.

30 Mar 2010

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.

26 Mar 2010

New experiments may hold clues for controlling cancer

A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

26 Mar 2010

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.

26 Mar 2010

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, announced today that it has obtained commitments from several investors to purchase 2.7 million shares of its common stock at $6.00 per share and warrants to purchase 540,000 shares of its common stock for gross proceeds of $16.2 million.

26 Mar 2010

How does a heart know when it's big enough?

25 Mar 2010

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

23 Mar 2010

Investment report on Arrowhead Research

BeaconEquity.com announces an investment report featuring Arrowhead Research Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

23 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

A California Institute of Technology -led team of researchers and clinicians has published the first proof that a targeted nanoparticle-used as an experimental therapeutic and injected directly into a patient's bloodstream-can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).

22 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

RNAi News and Research

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

SRU Biosystems extends product line with the introduction of BIND SCANNER

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

Scientists create genetic map to identify mechanism behind heart abnormalities

RXi Pharmaceuticals reports net loss of 28% for 2009

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

StockPreacher.com releases investment report on MDRNA

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

New experiments may hold clues for controlling cancer

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

How does a heart know when it's big enough?

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Investment report on Arrowhead Research

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Nanotechnology weapons for cancer

Caltech-led trial demonstrates feasibility of nanoparticles and RNAi-based therapeutics for treating cancer

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics